- Canada
- /
- Medical Equipment
- /
- TSX:HTL
These 4 Measures Indicate That Hamilton Thorne (CVE:HTL) Is Using Debt Reasonably Well
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved when a business collapses. As with many other companies Hamilton Thorne Ltd. (CVE:HTL) makes use of debt. But the more important question is: how much risk is that debt creating?
When Is Debt Dangerous?
Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. If things get really bad, the lenders can take control of the business. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. The first step when considering a company's debt levels is to consider its cash and debt together.
See our latest analysis for Hamilton Thorne
What Is Hamilton Thorne's Debt?
You can click the graphic below for the historical numbers, but it shows that as of March 2023 Hamilton Thorne had US$14.6m of debt, an increase on US$5.87m, over one year. However, it does have US$15.9m in cash offsetting this, leading to net cash of US$1.34m.
A Look At Hamilton Thorne's Liabilities
According to the last reported balance sheet, Hamilton Thorne had liabilities of US$12.7m due within 12 months, and liabilities of US$16.6m due beyond 12 months. Offsetting this, it had US$15.9m in cash and US$7.64m in receivables that were due within 12 months. So it has liabilities totalling US$5.74m more than its cash and near-term receivables, combined.
Of course, Hamilton Thorne has a market capitalization of US$142.8m, so these liabilities are probably manageable. But there are sufficient liabilities that we would certainly recommend shareholders continue to monitor the balance sheet, going forward. Despite its noteworthy liabilities, Hamilton Thorne boasts net cash, so it's fair to say it does not have a heavy debt load!
Shareholders should be aware that Hamilton Thorne's EBIT was down 29% last year. If that decline continues then paying off debt will be harder than selling foie gras at a vegan convention. There's no doubt that we learn most about debt from the balance sheet. But ultimately the future profitability of the business will decide if Hamilton Thorne can strengthen its balance sheet over time. So if you want to see what the professionals think, you might find this free report on analyst profit forecasts to be interesting.
Finally, a business needs free cash flow to pay off debt; accounting profits just don't cut it. While Hamilton Thorne has net cash on its balance sheet, it's still worth taking a look at its ability to convert earnings before interest and tax (EBIT) to free cash flow, to help us understand how quickly it is building (or eroding) that cash balance. During the last three years, Hamilton Thorne produced sturdy free cash flow equating to 58% of its EBIT, about what we'd expect. This cold hard cash means it can reduce its debt when it wants to.
Summing Up
While it is always sensible to look at a company's total liabilities, it is very reassuring that Hamilton Thorne has US$1.34m in net cash. So we don't have any problem with Hamilton Thorne's use of debt. When analysing debt levels, the balance sheet is the obvious place to start. However, not all investment risk resides within the balance sheet - far from it. Be aware that Hamilton Thorne is showing 2 warning signs in our investment analysis , you should know about...
If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.
Valuation is complex, but we're here to simplify it.
Discover if Hamilton Thorne might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSX:HTL
Hamilton Thorne
Develops, manufactures, and sells precision instruments, laboratory equipment, consumables, software, and services for the assisted reproductive technologies (ART), research, and cell biology markets.
Reasonable growth potential with adequate balance sheet.